ARTELO BIOSCIENCES (ARTL) Says ART27.13 Matched Semaglutide in Obese Mice
Nonclinical study showed roughly 20% weight loss on Artelo's oral cannabinoid agonist alone and about 40% when combined with semaglutide.
Artelo Biosciences (ARTL) said a nonclinical study of its oral, once-daily drug candidate ART27.13 produced weight loss comparable to semaglutide in obese mice, and roughly doubled that weight loss when the two were given together. In the diet-induced obesity model, ART27.13 as a monotherapy cut body weight from baseline by about 20% over four weeks, while the combination with semaglutide reached about 40% – bringing the animals to the body weight of lean, normal-weight controls.
